General Information of Drug Transporter (DT)
DT ID	DTD0456 Transporter Info
Gene Name	SLC6A4
Protein Name	Sodium-dependent serotonin transporter
Gene ID	6532
UniProt ID	P31645
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs25531
Site of GPD	chr17:30237328 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.1376/689 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:         20 Drugs in Total
Citalopram	Drug Info	Dementia	Correlated with the increased likelihood of side effects in patients (compare with Allele T)		[ 1]
Citalopram	Drug Info	Depression	Irrelevant to the drug response in patients (compare with Allele T)		[ 2]
Citalopram	Drug Info	Major Depressive Disorder	Irrelevant to the increased likelihood of remission in patients (compare with Allele T)		[ 3]
Fluoxetine	Drug Info	Major Depressive Disorder	Irrelevant to the drug response in patients (compare with Allele T)		[ 4]
Nortriptyline	N.A.	Death	Allele C is not associated with response to nortriptyline in people with Tobacco Use Disorder as compared to allele T.		[ 5]
Bupropion	N.A.	Death	Allele C is not associated with response to bupropion in people with Tobacco Use Disorder as compared to allele T.		[ 5]
Citalopram	N.A.	Death	Allele C is associated with increased likelihood of side effects when treated with citalopram in people with Dementia as compared to allele T.		[ 1]
Antipsychotics	N.A.	Death	Allele C is not associated with response to antipsychotics, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele T.		[ 6]
Haloperidol	N.A.	Death	Allele C is not associated with response to antipsychotics, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele T.		[ 6]
Olanzapine	N.A.	Death	Allele C is not associated with response to antipsychotics, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele T.		[ 6]
Risperidone	N.A.	Death	Allele C is not associated with response to antipsychotics, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele T.		[ 6]
Fluoxetine	N.A.	Death	Allele C is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to allele T.		[ 4]
Escitalopram	N.A.	Weight Gain	Allele C is not associated with response to escitalopram in people with Depressive Disorder, Major as compared to allele T.		[ 7]
Citalopram	N.A.	Weight Gain	Allele C is not associated with response to citalopram in people with Depressive Disorder, Major as compared to allele T.		[ 8]
Duloxetine	N.A.	Weight Gain	Allele C is not associated with response to duloxetine in people with Depressive Disorder, Major as compared to allele T.		[ 9]
Citalopram	N.A.	Weight Gain	Allele C is not associated with response to citalopram in people with Depression as compared to allele T.		[ 2]
Citalopram	N.A.	Weight Gain	Allele C is not associated with increased likelihood of remission when treated with citalopram in people with Depressive Disorder, Major as compared to allele T.		[ 3]
Venlafaxine	N.A.	Weight Gain	Allele C is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele T.		[ 10]
Ethanol	N.A.	Alcohol Abuse	Allele C is associated with decreased risk of Alcoholism due to ethanol as compared to allele T.		[ 11]
Fluoxetine	N.A.	Major Depressive Disorder	Allele C is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to allele T.		[ 4]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluoxetine	Drug Info	Major Depressive Disorder	Correlated with the increased reduced drug response risk in patients (compare with Genotype TT)		[ 12]
Fluoxetine	N.A.	Weight Gain	Genotypes CC + CT are associated with increased risk of reduced response when treated with fluoxetine in people with Depressive Disorder, Major as compared to genotype TT.		[ 12]
Fluoxetine	N.A.	Major Depressive Disorder	Genotypes CC + CT are associated with increased risk of reduced response when treated with fluoxetine in people with Depressive Disorder, Major as compared to genotype TT.		[ 12]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Venlafaxine	N.A.	Death	Genotype TT is associated with increased clinical benefit to venlafaxine in people with Anxiety Disorders as compared to genotypes CC + CT.		[ 13]
Citalopram	N.A.	Depression	The current evidence base suggests that there is no association between the rs25531 TT genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.		[ 2]
Fluoxetine	N.A.	Major Depressive Disorder	Patients with the TT genotype and Major Depressive Disorder who are treated with fluoxetine may be more likely to respond compared to patients with genotype CC or CT . Other genetic and clinical factors may also influence a patient's response.		[ 4]
Ethanol	N.A.	Alcohol Abuse	Patients with the TT genotype may be at an increased risk of developing alcohol dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.		[ 11]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Clozapine	N.A.	Death	Allele T is associated with response to clozapine in people with Schizophrenia.		[ 14]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Citalopram	N.A.	Depression	The current evidence base suggests that there is no association between the rs25531 CC genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.		[ 2]
Fluoxetine	N.A.	Major Depressive Disorder	Patients with the CC genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response.		[ 4]
Ethanol	N.A.	Alcohol Abuse	Patients with the CC genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.		[ 11]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Citalopram	N.A.	Depression	The current evidence base suggests that there is no association between the rs25531 CT genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.		[ 2]
Fluoxetine	N.A.	Major Depressive Disorder	Patients with the CT genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response.		[ 4]
Ethanol	N.A.	Alcohol Abuse	Patients with the CT genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype, but an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.		[ 11]
Genetic Polymorphism	rs57098334
Site of GPD	chr17:30221569-30221577 (GRCh38.p12)
GPD Type	Indel Insertion and Deletion
Allele(s) in dbSNP	ins(AGCCCACCC)8AGCCCACC / ins(AGCCCACCC)9AGCCCACC / ins(AGCCCACCC)11AGCCCACC
(AGCCCACCC)12	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Sertraline	Drug Info	Major Depressive Disorder	Irrelevant to the drug response in patients (compare with allele (AGCCCACCC)9)		[ 15]
Genotype (AGCCCACCC)10/(AGCCCACCC)10	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Sertraline	N.A.	Death	Genotype (AGCCCACCC)10/(AGCCCACCC)10 is not associated with response to sertraline in people with Panic Disorder as compared to genotype (AGCCCACCC)12/(AGCCCACCC)12.		[ 16]
Sertraline	N.A.	Major Depressive Disorder	Genotype (AGCCCACCC)10/(AGCCCACCC)10 is not associated with response to sertraline in people with Panic Disorder as compared to genotype (AGCCCACCC)12/(AGCCCACCC)12.		[ 16]
Sertraline	N.A.	Panic Disorder	Genotype (AGCCCACCC)10/(AGCCCACCC)10 is not associated with response to sertraline in people with Panic Disorder as compared to genotype (AGCCCACCC)12/(AGCCCACCC)12.		[ 16]
Genotype (AGCCCACCC)12	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Fluoxetine	N.A.	Death	Allele (AGCCCACCC)12 is not associated with response to fluoxetine in people with Depressive Disorder, Major.		[ 17]
Nortriptyline	N.A.	Death	Allele (AGCCCACCC)12 is not associated with response to nortriptyline in people with Tobacco Use Disorder as compared to genotypes (AGCCCACCC)10/(AGCCCACCC)10 + (AGCCCACCC)10/(AGCCCACCC)9.		[ 5]
Bupropion	N.A.	Death	Allele (AGCCCACCC)12 is not associated with response to bupropion in people with Tobacco Use Disorder as compared to genotypes (AGCCCACCC)10/(AGCCCACCC)10 + (AGCCCACCC)10/(AGCCCACCC)9.		[ 5]
Sertraline	N.A.	Death	Allele (AGCCCACCC)12 is not associated with response to sertraline in people with Depressive Disorder, Major as compared to allele (AGCCCACCC)9.		[ 15]
Sertraline	N.A.	Major Depressive Disorder	Allele (AGCCCACCC)12 is not associated with response to sertraline in people with Depressive Disorder, Major as compared to allele (AGCCCACCC)9.		[ 15]
Sertraline	N.A.	Panic Disorder	Allele (AGCCCACCC)12 is not associated with response to sertraline in people with Depressive Disorder, Major as compared to allele (AGCCCACCC)9.		[ 15]
Fluoxetine	N.A.	Depression	Allele (AGCCCACCC)12 is not associated with response to fluoxetine in people with Depressive Disorder, Major.		[ 17]
Fluoxetine	N.A.	Major Depressive Disorder	Allele (AGCCCACCC)12 is not associated with response to fluoxetine in people with Depressive Disorder, Major.		[ 17]
Genotype (CCCACCCGA)12/(CCCACCCGA)12	Click to Show/Hide the Full List of Affected Drugs:         17 Drugs in Total
Fluoxetine	N.A.	Death	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is not associated with increased response to fluoxetine in people with Depressive Disorder, Major.		[ 18]
Antidepressants	N.A.	Death	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with lack of remission and lack of response when treated with antidepressants in people with Depression.		[ 19]
Fluvoxamine	N.A.	Death	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is not associated with response to fluvoxamine in people with Depression.		[ 20]
Fluoxetine	N.A.	Death	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine and paroxetine in people with Depression.		[ 21]
Paroxetine	N.A.	Death	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine and paroxetine in people with Depression.		[ 21]
Fluoxetine	N.A.	Death	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major.		[ 22]
Sertraline	N.A.	Death	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major.		[ 22]
Antidepressants	N.A.	Depression	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased risk of adverse drug reaction after the second switch in treatment when treated with antidepressants in people with Depression.		[ 19]
Sertraline	N.A.	Major Depressive Disorder	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major.		[ 22]
Sertraline	N.A.	Panic Disorder	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major.		[ 22]
Paroxetine	N.A.	Depression	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine and paroxetine in people with Depression.		[ 21]
Fluoxetine	N.A.	Depression	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine and paroxetine in people with Depression.		[ 21]
Fluoxetine	N.A.	Major Depressive Disorder	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine and paroxetine in people with Depression.		[ 21]
Fluoxetine	N.A.	Depression	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is not associated with increased response to fluoxetine in people with Depressive Disorder, Major.		[ 18]
Fluoxetine	N.A.	Major Depressive Disorder	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is not associated with increased response to fluoxetine in people with Depressive Disorder, Major.		[ 18]
Fluoxetine	N.A.	Depression	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major.		[ 22]
Fluoxetine	N.A.	Major Depressive Disorder	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major.		[ 22]
Genotype (AGCCCACCC)12/(AGCCCACCC)12	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Antidepressants	N.A.	Depression	Patients with the (AGCCCACCC)12/(AGCCCACCC)12 genotype and depression who are treated with antidepressants may have an increased risk of adverse drug reactions after switching treatment for the second time as compared to non-(AGCCCACCC)12/(AGCCCACCC)12 genotypes. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 19]
Fluoxetine	N.A.	Depression	Patients with the (AGCCCACCC)12/(AGCCCACCC)12 genotype and depression who are treated with fluoxetine may be more likely to respond to treatment as compared to patients with the non-(AGCCCACCC)12/(AGCCCACCC)12 genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 17]
Fluoxetine	N.A.	Major Depressive Disorder	Patients with the (AGCCCACCC)12/(AGCCCACCC)12 genotype and depression who are treated with fluoxetine may be more likely to respond to treatment as compared to patients with the non-(AGCCCACCC)12/(AGCCCACCC)12 genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 17]
Genotype (CCCACCCGA)9	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Sertraline	N.A.	Major Depressive Disorder	Patients with the (CCCACCCGA)9 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 16]
Sertraline	N.A.	Panic Disorder	Patients with the (CCCACCCGA)9 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 16]
Genotype (CCCACCCGA)10	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Sertraline	N.A.	Major Depressive Disorder	Patients with the (CCCACCCGA)10 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 16]
Sertraline	N.A.	Panic Disorder	Patients with the (CCCACCCGA)10 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 16]
Genotype CCCACCCGA)12/(CCCACCCGA)12	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Sertraline	N.A.	Major Depressive Disorder	Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with sertraline may have a better response to treatment as compared to other genotypes. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 16]
Sertraline	N.A.	Panic Disorder	Patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype and depression who are treated with sertraline may have a better response to treatment as compared to other genotypes. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 16]
Genotype (CCCACCCGA)9/(CCCACCCGA)9	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Paroxetine	N.A.	Depression	Patients with the (CCCACCCGA)9/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 21]
Genotype (CCCACCCGA)10/(CCCACCCGA)9	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Paroxetine	N.A.	Depression	Patients with the (CCCACCCGA)10/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 21]
Genotype (CCCACCCGA)10/(CCCACCCGA)10	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Paroxetine	N.A.	Depression	Patients with the (CCCACCCGA)10/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 21]
Genotype (CCCACCCGA)12/(CCCACCCGA)9	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Paroxetine	N.A.	Depression	Patients with the (CCCACCCGA)12/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 21]
Genotype (CCCACCCGA)12/(CCCACCCGA)10	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Paroxetine	N.A.	Depression	Patients with the (CCCACCCGA)12/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely respond to treatment as compared to patients with the (CCCACCCGA)12/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 21]
Genetic Polymorphism	rs1042173
Site of GPD	chr17:30197993 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C
Minor Allele Frequency	A=0.5280/1044 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Ondansetron	N.A.	Death	Genotype AA is associated with increased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype when treated with ondansetron in people with Alcoholism as compared to allele C.		[ 23]
Ondansetron	N.A.	Alcohol Abuse	Genotype AA is associated with increased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype when treated with ondansetron in people with Alcoholism as compared to allele C.		[ 23]
Morphine	N.A.	Pain	Patients with cancer pain and the AA genotype may have increased morphine dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's morphine dose requirements.		[ 24]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Morphine	N.A.	Alcohol Abuse	Genotype CC is associated with decreased dose of morphine in people with Lung Neoplasms and Pain as compared to genotypes AA + AC.		[ 24]
Ondansetron	N.A.	Alcohol Abuse	Patients with the CC genotype who are treated with ondansetron may have decreased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.		[ 23]
Morphine	N.A.	Pain	Genotype CC is associated with decreased dose of morphine in people with Lung Neoplasms and Pain as compared to genotypes AA + AC.		[ 24]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Ondansetron	N.A.	Alcohol Abuse	Patients with the AC genotype who are treated with ondansetron may have decreased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.		[ 23]
Morphine	N.A.	Pain	Patients with cancer pain and the AC genotype may have increased morphine dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's morphine dose requirements.		[ 24]
Genetic Polymorphism	rs3813034
Site of GPD	chr17:30197786 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G / A>T
Minor Allele Frequency	A=0.5300/1048 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Risperidone	N.A.	Weight Gain	Genotype AA is associated with increased likelihood of Weight gain when treated with risperidone in people with Schizophrenia as compared to genotypes AC + CC.		[ 25]
Genetic Polymorphism	rs2020933
Site of GPD	chr17:30234737 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>T
Minor Allele Frequency	A=0.8410/1664 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Atorvastatin	N.A.	Myalgia	Allele T is not associated with increased risk of Myalgia unspecified when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele A.		[ 26]
Pravastatin	N.A.	Myalgia	Allele T is not associated with increased risk of Myalgia unspecified when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele A.		[ 26]
Simvastatin	N.A.	Myalgia	Allele T is not associated with increased risk of Myalgia unspecified when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele A.		[ 26]
Genetic Polymorphism	rs140700
Site of GPD	chr17:30216371 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G / C>T
Minor Allele Frequency	C=0.9260/1832 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Atorvastatin	N.A.	Myalgia	Allele T is not associated with increased risk of Myalgia unspecified when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele C.		[ 26]
Pravastatin	N.A.	Myalgia	Allele T is not associated with increased risk of Myalgia unspecified when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele C.		[ 26]
Simvastatin	N.A.	Myalgia	Allele T is not associated with increased risk of Myalgia unspecified when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele C.		[ 26]
Genetic Polymorphism	rs4251417
Site of GPD	chr17:30224840 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	C=0.9720/1923 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Ethanol	N.A.	Alcohol Abuse	Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.		[ 11]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Ethanol	N.A.	Alcohol Abuse	Patients with the CC genotype may be at an increased risk of developing alcohol dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.		[ 11]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Ethanol	N.A.	Alcohol Abuse	Patients with the CT genotype may be at an increased risk fo developing alcohol dependence as compared to patients wit the TT genotype, but a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also a affect a patient's risk of developing alcohol dependence.		[ 11]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Ethanol	N.A.	Alcohol Abuse	Patients with the TT genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.		[ 11]
Genetic Polymorphism	rs2066713
Site of GPD	chr17:30224647 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.7370/1458 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Ethanol	N.A.	Alcohol Abuse	Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.		[ 11]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Ethanol	N.A.	Alcohol Abuse	Patients with the AA genotype may be at an increased risk of developing alcohol dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.		[ 11]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Ethanol	N.A.	Alcohol Abuse	Patients with the AG genotype may be at an increased risk of developing alcohol dependence as compared to patients with the GG genotype but a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.		[ 11]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Ethanol	N.A.	Alcohol Abuse	Patients with the GG genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.		[ 11]
Genetic Polymorphism	rs7224199
Site of GPD	chr17:30196708 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	G=0.4250/841 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Morphine	N.A.	Alcohol Abuse	Allele T is not associated with dose of morphine in people with Lung Neoplasms and Pain as compared to allele G.		[ 24]
References
1	Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. Int Clin Psychopharmacol. 2010 Jan;25(1):37-45.
2	SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet. 2009 Apr 5;150B(3):341-51.
3	SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. Am J Geriatr Psychiatry. 2014 Nov;22(11):1140-8.
4	The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. J Affect Disord. 2010 Dec;127(1-3):343-51.
5	Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation. Addiction. 2012 Jan;107(1):178-87.
6	Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry Res. 2010 Feb 28;175(3):189-94.
7	Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol. 2009 Jun;19(6):451-6.
8	Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry. 2007 Mar 15;61(6):734-42.
9	Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry. 2010 Jun 01;67(11):1110-3.
10	Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults. Am J Psychiatry. 2017 May 1;174(5):468-475.
11	Psychiatric disorders and SLC6A4 gene variants: possible effects on alcohol dependence and alzheimer's disease. Mol Biol Rep. 2020 Jan;47(1):191-200.
12	Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry. 2005 Sep 1;58(5):374-81.
13	Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. 2013 Oct;13(5):464-9.
14	Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics. J Psychiatr Res. 2010 Dec;44(16):1158-62.
15	Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet Test. 2008 Jun;12(2):225-31.
16	The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder. BMC Psychiatry. 2020 Jul 28;20(1):388.
17	Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry. 2004 Sep;9(9):879-89.
18	Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 2006;6(1):27-33.
19	Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J. 2009 Feb;9(1):61-70.
20	A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res. 2002 Aug 30;111(2-3):235-9.
21	Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 2000 Jan 17;11(1):215-9.
22	Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA. 2006 Oct 04;296(13):1609-18.
23	Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry. 2011 Mar;168(3):265-75.
24	Correlations of analgesic dosage of morphine with SLC6A4 gene polymorphisms in patients with lung cancer. Eur Rev Med Pharmacol Sci. 2020 May;24(9):5046-5052.
25	A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population. Pharmacogenomics. 2015 Nov;16(17):1943-9.
26	Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve. 2007 Sep;36(3):329-35.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.